Jaxteran

Dimethyl fumarate, the active ingredient in Jaxteran, is an immunomodulating agent presented as an oral formulation for oral use. It treats relapsing‑remitting multiple sclerosis in adults.

GNH USA supplies Jaxteran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jaxteran is an immunomodulating therapy used in the management of multiple sclerosis.

Relapsing‑remitting multiple sclerosis: reduces the frequency of clinical relapses and slows disability progression.

Common Side Effects: - Flushing: transient warmth and redness, often on the face or neck. - Gastrointestinal discomfort: nausea, abdominal pain, or diarrhea. - Lymphopenia: mild reduction in lymphocyte count. - Headache: mild to moderate intensity. - Upper respiratory tract symptoms: cough or sore throat. - Pruritus: mild skin itching.

Serious or Rare Side Effects: - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection. - Severe lymphopenia: marked decrease in lymphocytes increasing infection risk. - Hepatic injury: elevated liver enzymes or hepatitis. - Anaphylaxis: severe allergic reaction with airway compromise. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Acute pancreatitis: inflammation of the pancreas.

Before initiating therapy, clinicians should evaluate baseline laboratory values and patient history.

Monitor lymphocyte counts: check regularly to detect lymphopenia. Assess infection risk: avoid in patients with active infections. Avoid use in known hypersensitivity: discontinue if allergic reaction occurs. Use caution in hepatic impairment: adjust monitoring as needed. Pregnancy: risk unknown, discuss benefits versus risks with a physician. Store at ambient temperature: keep in the original container, protect from moisture.

Dimethyl fumarate may interact with several drug classes.

Major Interactions (Avoid): - Immunosuppressants: may increase infection risk. - Live vaccines: contraindicated due to reduced immune response. - Strong CYP inducers: may lower dimethyl fumarate exposure. - Antiepileptic drugs (e.g., carbamazepine): may reduce efficacy. - Antiretroviral therapy: potential for altered immune modulation.

Moderate Interactions (Monitor Closely): - Antacids: may affect gastrointestinal absorption. - Beta‑blockers: monitor blood pressure changes. - Non‑live vaccines: assess immune response adequacy. - NSAIDs: watch for additive gastrointestinal irritation. - Alcohol: may exacerbate flushing and gastrointestinal symptoms.